PALB2 has a critical role in homologous recombination repair, such that tumours which are associated with pathogenic variants in PALB2 demonstrate homologous recombination repair deficiency [107], and there is increasing evidence to suggest that such tumours may demonstrate a favourable response to platinum-based chemotherapy and PARP inhibitors, such that the American College of Medical Genetics recommends the consideration of the same systemic options for the carriers of PALB2 variants as for carriers of pathogenic variants in BRCA1/BRCA2 [106]. This evidence concerns the gene BRCA2 and neoplasm.